Avanos Medical, Inc. (AVNS)
- Previous Close
12.58 - Open
12.64 - Bid 5.06 x 900
- Ask --
- Day's Range
12.57 - 12.79 - 52 Week Range
11.84 - 25.36 - Volume
406,766 - Avg. Volume
520,408 - Market Cap (intraday)
584.987M - Beta (5Y Monthly) 1.14
- PE Ratio (TTM)
-- - EPS (TTM)
-8.27 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; OrthogenRx knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
avanos.comRecent News: AVNS
View MorePerformance Overview: AVNS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVNS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVNS
View MoreValuation Measures
Market Cap
584.99M
Enterprise Value
628.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.84
Price/Book (mrq)
0.70
Enterprise Value/Revenue
0.91
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-55.80%
Return on Assets (ttm)
2.26%
Return on Equity (ttm)
-36.78%
Revenue (ttm)
689.2M
Net Income Avi to Common (ttm)
-380.2M
Diluted EPS (ttm)
-8.27
Balance Sheet and Cash Flow
Total Cash (mrq)
97M
Total Debt/Equity (mrq)
16.79%
Levered Free Cash Flow (ttm)
131.31M